Venu Jain

Prof. Venu Jain


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
VJVenu Jain
Venu Jain
HBHayley Bos
Hayley Bos
EBEmmanuel Bujold
Emmanuel Bujold

1 June 2020 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
VJVenu Jain
Venu Jain
SMSarah D. McDonald
Sarah D. McDonald
WMWilliam R. Mundle
William R. Mundle
DFDan Farine
Dan Farine

18 May 2023 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
VJVenu Jain
Venu Jain
RGRobert Gagnon
Robert Gagnon

1 September 2021 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
VJVenu Jain
Venu Jain
COCandace O'QUinn
Candace O'QUinn
MHMichiel Van Den Hof
Michiel Van Den Hof

19 December 2012 in American Journal of Perinatology Reports
Verified
Journal Article
Open access
PDF file
AFAshley Fyfe-Brown
Ashley Fyfe-Brown
GCGwen Clarke
Gwen Clarke
KNKara Nerenberg
Kara Nerenberg
SCSujata Chandra
Sujata Chandra
VJVenu Jain
Venu Jain
Thrombotic thrombocytopenia purpura (TTP) is an infrequent but serious disease. Pregnancy is a known risk factor for presentation or relapse of TTP. Difficulties in differentiating TTP from preeclampsia/HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome, and current treatment recommendations are discussed in this case report. A woman with previously treated and stable TTP had a relapse at 36 weeks' gestation. Careful surveillance led to an early diagnosis. Severe disease in the peripartum period was treated successfully with cryosupernatant plasma-based plasmapheresis and platelet transfusion, with good maternal and neonatal outcomes. Cryosupernatant plasma is a viable alternative to fresh frozen plasma for plasmapheresis for TTP and may offer some therapeutic and logistical advantages. Platelet transfusion can be undertaken safely if needed to prevent or treat significant hemorrhage.

19 November 2023 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
VJVenu Jain
Venu Jain
EBEmmanuel Bujold
Emmanuel Bujold